UK Pricing Scheme Negotiations Should Include Broader Representation
Generics and biosimilars manufacturers and patients should have greater influence on UK pricing scheme negotiations.
You may also be interested in...
Negotiations on the successor to the UK’s 2019 voluntary drug pricing scheme are due to start in April 2023. The industry body, the ABPI, is calling for a clean sheet approach, but others suggest that could make it almost impossible to reach agreement in less than a year and that reform may be a more realistic proposition.
Many pharma firms are considering cutting their investment in clinical trials or reducing their supply to the UK market next year, a survey by industry group EMIG found.
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.